Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis

• Main Authors: Lee, Bei Shi, Hards, Kiel, Engelhart, Curtis A., Hasenoehrl, Erik J., Kalia, Nitin Pal, Mackenzie, Jared S., Sviriaeva, Ekaterina, Chong, Sherilyn Shi Min, Manimekalai, Malathy Sony S., Koh, Vanessa H., Chan, John, Xu, Jiayong, Alonso, Sylvie, Miller, Marvin J., Steyn, Adrie J. C., Grüber, Gerhard, Schnappinger, Dirk, Berney, Michael, Cook, Gregory M., Moraski, Garrett C., Pethe, Kevin
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2021
• Subjects: Science::Chemistry::Biochemistry; Antibiotic-tolerance; Cytochrome bcc-aa3
• Online Access: https://hdl.handle.net/10356/149224
• Institution: Nanyang Technological University

The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F1F0 ATP synthase, small molecules targeting other components of the oxidative phosphorylation pathway have be...